AnaptysBio, Inc.
NASDAQAnaptysBio heads into the back half of June with its most striking divergence in months: options traders have turned sharply bullish while short sellers quietly add to one of biotech's larger short positions. The options signal is the standout this week. The put/call ratio has collapsed to 0.61, nearly three standard deviations below its 20-day average of 2.03 — a swing so extreme…
Snapshot as of 28 Jun 2026
AnaptysBio heads into the back half of June with its most striking divergence in months: options traders have turned sharply bullish while short sellers quietly add to one of biotech's larger short positions. The…
AnaptysBio enters the week in a striking tension: short interest has climbed to a meaningful 17.5% of free float while options traders have pivoted to their most bullish posture in months — a split that makes the next…
AnaptysBio enters the post-earnings session as a stock at war with itself — fresh evidence of commercial weakness on one side, a chorus of analysts lifting targets on the other. Q1 results released Tuesday evening were…
AnaptysBio reports Q1 results on May 15 with short sellers quietly adding pressure just as the stock trades near its lowest level in months. The short interest angle is the standout setup heading into this print. Bears…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ANAB — free to start on ORTEX.
Sign up for free →Open ANAB on ORTEX